Fig. 9From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi ArabiaThe 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse (c) based on day-29 (end-of-induction) minimal residual disease (MRD) level (percent scores) > 0.01%. HR hazard ratioBack to article page